Novavax
在场
是其中之一......
Novavax 是一家在股票代码 NVAX (US) 下上市的公司。
Novavax 在 2 个国家有直接业务。
高管
查看带有其 37 名主要高管的组织结构图
Novavax 搜索最多的简介
高管在Novavax变化
- Ruxandra Draghia-Akli已作为Executive Vice President and Head of Research & Development加入公司 (新闻发布的2024九月26号).
创建提醒
跟踪 Novavax 的高管变动
生物技术
Novavax 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Novavax 的最新新闻稿
- U.S. CDC and ACIP Recommend Additional COVID-19 Vaccine Dose for Older Individuals and Those Who Are Immunocompromised - Oct 24, 2024
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial - Oct 16, 2024
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development - Sep 25, 2024
- Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S. - Sep 13, 2024
- Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - Aug 30, 2024
- Novavax to Participate in Upcoming September Conferences - Sep 4, 2024
- Novavax Continues to Work with the U.S. FDA on Authorization of 2024-2025 Formula COVID-19 Vaccine - Aug 22, 2024
- Press releases & statements | Novavax Investor Relations
- Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall - Apr 26, 2024
- Novavax to Supply Updated COVID-19 Vaccine to Private Healthcare Providers in the United Kingdom - Apr 18, 2024
- View more press releases Close
通过电子邮件
